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ABSTRACT

MONITORING, IDENTIFICATION AND INTERVENTION FOR METABOLIC
DISORDERS IN VETERANS WITH PSYCHOTIC DISORDERS.
Michael H. Swetye, Christopher B. Ruser, Mohini Ranganathan, and Robert M.
Rohrbaugh. Department of Psychiatry, Veteran Affairs Connecticut Healthcare System,
West Haven, CT.

In light of growing evidence that certain antipsychotics may cause potentially lifethreatening metabolic side-effects, the purpose of this study was to determine how
regularly mental health clinicians (MHCs) currently monitor and manage metabolic
abnormalities in overweight and obese patients with psychotic disorders. We
hypothesized that MHCs monitor, identify and intervene for metabolic abnormalities in
their patients at significantly lower rates than primary care physicians (PCCs), and that
such rates may jeopardize patient health.
We performed a one-year cross-sectional medical record review of primary care
and mental health routine outpatient visit notes from the West Haven Campus of the
Veteran Affairs Connecticut Healthcare System. We reviewed the records of a cohort of
123 veterans who met the following inclusion criteria: (1) primary diagnosis of
schizophrenia or schizoaffective disorder; (2) at least one routine mental health visit at
the West Haven VA facility between July 1, 2005 and June 30, 2006; and (3) overweight
or obese, as determined by a body mass index (BMI) > 25. We excluded all deaths.
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The 123 subjects were predominantly white and male (56% and 93%,
respectively) with an average body mass index (BMI) of 32.4 (SD=5.4). 97% of subjects
were taking an antipsychotic of some sort, and 85% were taking a second-generation
antipsychotic.
Zero diagnoses of metabolic syndrome and zero waist-size measurements were
documented by PCCs or MHCs. The following differences in documentation were found
between PCCs and MHCs, respectively: weight (85% vs. 11%; p<0.001); BMI (48% vs.
0%; p<0.001); identified weight as an issue (45% vs. 28%; p<0.005); identified the link
between antipsychotics and weight issues (10% vs. 12%; not significant); made diet and
exercise recommendations (42% vs. 19%; p<0.001); ordered a weight-management
referral (21% vs. 3%; p<0.001); ordered or considered ordering a change of antipsychotic
medication or dose due to weight-related issues (6% vs. 3%; not significant). PCCs
ordered laboratory tests at much higher rates than MHCs, including blood glucose,
thyroid stimulating hormone, urinalysis, lipid panel, and hemoglobin A1C (differences
were large and significant).
We concluded that MHCs monitor, identify and intervene for metabolic
abnormalities in their patients at significantly lower rates than PCCs, and that such rates
are unacceptably low. The problem is one of a systemic failure in quality control and
may pose a danger to patients. We advocate a rapid organizational response and systemic
changes at the local and national level to improve quality.
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INTRODUCTION

Historical Background: Metabolic Derangement, Psychotic Disorders, and
Antipsychotics

Well before the advent of antipsychotics there was a string of clinicians who had
associated psychotic disorders with metabolic abnormalities. In 1904 Kraeplin described
an association between weight gain and the regression of dementia praecox symptoms (1,
2). In1926, Kasanin described an association between schizophrenia and elevated blood
glucose (3). Kooy, writing in 1919, associated psychotic disorders with abnormal levels
of blood glucose (4). In 1947 Kryspin-Exner observed patients gaining weight as soon as
or before symptoms improved (2, 5).
Even in the antipsychotic era, some investigators have postulated that there are
potentially drug-independent associations between schizophrenia and metabolic
dysfunction (6). Furthermore, Brown et al. and others have shown that determining the
causes of metabolic dysfunction in psychotic patients is complicated by the unhealthy
lifestyle that is observed in many such patients, a finding that makes it more difficult to
delineate drug-induced from disease or behavior-induced metabolic dysfunction in
psychotic patients (7, 8).
With the introduction of chlorpromazine into clinical practice by Smith-Kline and
French in 1952 and the subsequent explosion of antipsychotic discovery and use,
antipsychotics emerged as a potential cause of metabolic abnormalities in psychotically
disordered patients (9). In 1954 Dobkin et al. found that normal volunteers responded to
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injected chlorpromazine with increased blood glucose levels (10). Then in 1960 Klett and
Caffey associated weight gain with the clinical efficacy of phenothiazine derivatives (2,
11). Singh et al. found similar associations in a study published in 1970 (2, 12).
The first atypical antipsychotic, clozapine, became commercially available in
Europe in 1971 (13). By the mid-1990’s several atypical antipsychotics had been
developed and were being prescribed by physicians (13). Atypical, or second-generation,
antipsychotics were originally greeted with much fanfare because they caused fewer
extrapyramidal side-effects than first-generation antipsychotics. Also, they were hailed as
more effective at relieving the negative symptoms of schizophrenia. Clozapine, in
particular, was considered more clinically effective than any of the first-generation
antipsychotics, despite its dangerous side-effect profile. As the use of atypical
antipsychotics grew rapidly, investigators began to notice patterns of side-effects related
to metabolism. Studies suggested an association between the atypical anti-psyschotic
medications and weight gain, metabolic syndrome, and even diabetes. All of this
literature will be discussed extensively in subsequent sections of this thesis.
Recently, as investigators and physicians have become more aware of the
metabolic side effects of antipsychotics, and as concern has grown about the negative
health consequences of overweight and obesity, academics have begun to examine the
health services question of how doctors and other healthcare providers monitor and
manage the metabolic status of patients with psychotic disorders. In light of this context,
it has become questionable whether the common de facto divide between psychiatry and
the rest of medicine is truly in the best interest of patients. At present, it is understood in
the medical profession that many psychiatrists in the outpatient setting do not regularly
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conduct physical exams or laboratory tests, and that they do not communicate with any
regularity with internists or surgeons.

Epidemiology and Health Effects of Overweight and Obesity

Based on the 1999-2000 National Health and Nutrition Examination Survey
(NHANES), over 60% of the United States population is overweight and over 25% are
obese (14). These conditions are associated with an array of co-morbidities, particular
cardiovascular disease, hypertension and diabetes (14). Obesity-associated direct costs
among US adults may exceed 5% of all US healthcare expenditures (15). In the veteran
population the figures are worse than in the general population: over two in three are
overweight or obese, and more than one in three is classified as obese (14). A study by
Mokdad et al. found that weight-related factors such as poor diet and physical inactivity
followed tobacco as the leading actual causes of death in the United States in the year
2000, and that they may soon become the greatest actual causes of death (16). The
Institute of Medicine found that weight loss as low as 5% of total body weight was
associated a meaningful reduction of morbidity and mortality (17, 18). One would then
suspect that a similar gain in weight might be associated with the converse (17).
Guidelines for categorizing weight were set forth by a study performed by the National
Institutes of Health (NIH) in 1998 (19, 20). It was found that health risks increase as
patients moved from normal weight through the higher weight categories (17, 21).
Although considerable evidence has pointed to the adverse health effects of
overweight and obesity, a provocative recent study by Flegal et al. in 2007 suggested that
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relative to a normoweight population, overweight was not associated with cause-specific
death from cancer or cardiovascular disease (22). Additionally, overweight was actually
associated with a decrease in non-cancer, non-cardiovascular deaths (22). Obesity was
associated with increased cause-specific mortality from cardiovascular disease and
certain obesity-related cancers but it was not associated with mortality from non-cancer,
non-cardiovascular causes (22). When combined, overweight and obesity were associated
with increased cause-specific deaths from diabetes and kidney disease (22). This study
raises the question of what the real implications for overweight are relative to
normoweight, given that prior to this study one might have assumed that overweight was
a broadly negative condition. The results even suggest that for certain categories of
disease overweight may be protective. Flegal’s study does appear, however, to lend
further support to the claim that obesity leads to adverse health outcomes, particularly
adverse cardiovascular outcomes. There also appears to be a concerning association
between overweight and obesity, as a combined category, and diabetes and kidney
disease. Even though overweight appears to be more benign than obesity, one must be
concerned that the development of overweight in any given patient may ultimately lead to
obesity.
Unfortunately, reversing overweight and obesity is difficult, though surgical,
behavioral and pharmacological approaches to treatment do exist. Due to the risks posed
by obesity, in particular, and the difficult of treatment, factors that contribute to the
development of the condition must be mitigated by physicians whenever possible,
particularly when such factors are related to medical treatment itself.
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Antipsychotics and Weight

Due to the co-morbidities associated with overweight and obesity, it is concerning
that there is strong evidence showing that certain antipsychotic medications cause weight
gain – evidence that we will return to in detail at a later point. The high prevalence of
antipsychotic treatment in populations of patients with psychotic disorders makes this
group of patients particularly at risk for developing overweight and obesity. The
psychotic population is also at risk simply because it is part of the general US population,
where overweight and obesity are increasing at alarming rates (14). In addition, patients
with psychotic disorders often have impairments in self-care that place them at risk for
unhealthy lifestyles and hence weight gain (7, 8). Indeed, patients with serious mental
illness have been shown to be at increased risk of developing obesity (6, 23-25), and
obesity has been associated with excess deaths from cardiovascular disease (22). Also,
schizophrenia is associated with significantly elevated rates of cardiovascular disease
relative to the general population (26, 27), and this risk could be magnified by co-morbid
metabolic dysfunction.
Treatment-associated weight gain concerning not only because of it may increase
medical morbidity and mortality, but also because it may be a factor in reducing
psychiatric medication compliance (17, 28-30), although this association has been
disputed by some studies (31). Weight gain may have a negative impact on the self-image
and social status of psychotic patients (30). Indeed, weight gain in patients with
schizophrenia has been shown to have a negative impact on quality of life (17, 30).
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First-generation antipsychotics have been linked to weight gain, although in
general the literature shows less concern about these drugs relative to the secondgeneration antipsychotics. A 1999 meta-analysis by Allison et al. used a random effects
model to understand the impact of various antipsychotics on weight (17). The
investigators found that haloperidol, chlorpromazine and thioridazine/mezoridazine were
all associated with statistically significant weight gain (17). Fluphenazine, molindone and
placebo were not associated with weight gain, although non-pharmacologic control was
associated with a weight gain similar to haloperidol (17). The mean estimated statistically
significant weight gain for first-generation antipsychotics at 10 weeks ranged from
approximately 1.08 kg for haloperidol to 3.19 kg for thioridazine/mesoridazine (17).
These results are of course limited by the quality of studies as well as issues such as
dosing. Interestingly, the weight effect of the first-generation antipsychotics does not
appear related to chemical structure or potency (2). Some studies have suggested that
molindone and diphenylbutylpiperidine pimozide may actually induce weight loss of
several kilograms (17, 32-34). Interestingly, early studies suggested that successful
treatment with chlorpromazine was associated with weight gain, whereas weight loss was
associated with worsening symptoms (35). This finding lines up with the early
observations by Kraeplin about weight-associated symptom improvement and
deterioration in schizophrenics (1).
Second-generation antipsychotics have been closely associated with weight gain.
Clozapine is one of the best studied atypicals, and there is a well documented association
between its use and weight gain. Allison et al.’s meta-analysis from 1999 showed a
statistically significant mean gain of 4.45 kg associated with clozapine treatment at 10
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weeks (17). Published in 2000, Henderson et al.’s five-year prospective naturalistic study
of 82 patients taking clozapine found a mean weight gain of 11.6 kg over four years, and
weight gain did not level off until month 46 (36). Olanzapine has been very clearly linked
to weight gain as well (17). Risperidone appears to cause less weight gain than
olanzapine, but the gains are still significant (17). Although quetiapine is a newer drug,
there is some evidence that it also causes significant weight gain (17, 37). Ziprasidone
appears to be the one atypical antipsychotic with limited impact on weight (17).
Allison’s meta-analysis showed no significant association between ziprasidone and
weight gain (17). This offers clinicians a pharmacologic alternative to be considered if
their patients gain significant weight on a non-ziprasidone atypical. It should be reiterated
that according to the same meta-analysis, placebo was associated with weight loss.
Although this relationship did not reach statistical significance, it does suggest that the
weight gain associated with atypical antipsychotics is in fact drug-related.

Antipsychotics and Diabetes

Diabetes is a disease characterized by abnormally elevated blood glucose levels.
The disease is an emerging epidemic in the United States (38). From 2000-2007 the
incidence of diabetes in the United States increased by 54% (39). According to the Center
for Disease Control, in 2004 15.2 million Americans had diabetes (www.cdc.gov).
Particularly worrisome is the growing prevalence and incidence of type 2 diabetes, a
disease of insulin-resistance, which is often associated with obesity and is contributing to
much of the overall growth in the diabetes disease burden. Some have estimated that 90%
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of type 2 diabetes can be attributed to excess weight (40). Diabetes affects almost every
organ system and is associated with numerous serious health risks, including coronary
artery disease, stroke, peripheral neuropathy, peripheral vascular disease, retinopathy,
kidney disease, and gastroparesis. Furthermore, diabetics are at further risk of
complications when in a hospital setting or after surgery (41-43).
Investigators have noted an association between schizophrenia and diabetes. This
association was shown to exist before the widespread use of atypical antipsychotics (44,
45). Nevertheless, in recent years antipsychotics – particularly atypical antipsychotics –
have been blamed for the rising incidence of diabetes in psychotic patients (46, 47). In a
recent study by Srihari et al. that examined the prevalence and management of type 2
diabetes in patients receiving antipsychotic medications, diabetes was two-and-a-half
times as prevalent in the study population than in the general population (48). The
authors found that 71% of the 494 patients were taking one or more atypical
antipsychotics (48). In a naturalistic study of clozapine-naïve patients, it was found that
over a five-year period of treatment with clozapine, 36.6% of patients developed diabetes
(36). Interestingly, no significant risk of diabetes was attributed to weight gain, use of
valproate or clozapine dosing (36). In a large epidemiologic study of 56,849
schizophrenic patients taking antipsychotics over the span of 1-2 years, Leslie and
Roesnheck suggested that the attributable risks of diabetes associated with atypical
antipsychotics was small – ranging from 0.05% for risperidone to 2.03% for clozapine
(49). Interestingly, the attributable risk for quetiapine and risperidone was not
significantly different from that for conventional antipsychotics (49). Clozapine and
olanzapine had the highest risk (49). Yet in a cross-sectional study of 38,632 schizphrenic
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patients on antipsychotics it was found that patients taking atypical antipsychotics were
9% more likely to have diabetes than those who received typical antipsychotics (50). The
association of atypical antipsychotics and increased prevalence of diabetes was even
stronger in patients younger than 40 (50).
A paper by Dixon et al. suggested that patients who had schizophrenia and
diabetes had better outcomes, as measured by HbA1c, than patients with no severe
mental illness (51). This suggests although psychotic disorders and the drugs used to treat
them predispose patients to developing diabetes, such patients are not necessarily unable
to manage their diabetes. If that is the case beyond this study sample, it raises the
importance of monitoring for the development of diabetes and then intervening – such
interventions may be as effective or more effective in schizophrenic patients as in nonschizophrenic patients. Notably, patients taking olanzapine had higher HbA1c levels than
patients taking other antipsychotics (51).
Gianfrancesco et al. examined the odds of developing type 2 diabetes in diabetesnaïve patients who were treated with various antipsychotics using data from 2.5 million
patients cared for by managed care and insurance companies(52). The study period was
12 months, and patients reporting diabetes up to 8 months prior to the study were
excluded (52).

Olanzapine, clozapine and certain first generation antipsychotics

increased the risk of developing diabetes significantly, whereas risperidone did not
increase risk relative to untreated patients (52). The finding about risperidone aligns with
Sernyak’s study (50). In support of Gianfrancesco et al.’s findings, in 2004 Citrome et al.
found that exposure to multiple second-generation antipsychotics or clozapine or
quetiapine significantly increased the risk of treatment-emergent diabetes mellitus (53).
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Regarding treatment, Klein et al. published an interesting article suggesting that
metformin is an effective intervention for weight gain, decreased insulin sensitivity, and
abnormal glucose metabolism related to atypical antipsychotics (54). The limitation of
this study is that it was conducted in children and adolescents; nevertheless, it may be
translatable to adult patients and should be studied in that population. In fact, a recent
study from China, conducted by Wu et al., investigated the value of interventions in 128
schizophrenic patients using atypical antipsychotics. They found that after a 12-week
period, patients who received dietary education and partially supervised exercise,
metformin, or both, had significant weight loss and reduced insulin resistance relative to
drug placebo (55).

Antipsychotics and Blood Glucose Levels

A growing body of literature has suggested that antipsychotic use may lead to
changes in blood glucose levels (without necessarily leading to diabetic levels) (56-60).
Lindenmayer et al. published a prospective randomized double blind trial in 2003 with
157 patients with schizoaffective or schizophrenic disorder to look at the association
between antipsychotics and blood glucose level (61). The study was conducted over 14
weeks (61). Baseline blood glucose levels were taken before the patients were started on
therapy, and included a 6-week fixed dose period an 8-week variable dose period (61).
They found that clozapine, olanzapine, and haloperidol were associated with elevated
levels of fasting plasma glucose levels (61). Risperidone was not associated with
significant changes in blood glucose (61). Most of the elevations of plasma glucose did
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not lead to levels associated with the diagnosis of diabetes, although approximately 14%
of patients did develop diabetic-levels of blood glucose during the course of the study
(61). However, given Wilson et al.’s finding (below) that glucose intolerance may more
labile in patients receiving atypical antipsychotics, one wonders whether the point fasting
blood glucose levels used in this study could be misleading (62).
A particularly concerning result was noted in a 2002 study by Wilson et al., which
examined data from 126 patients treated with atypical antipsychotics. The investigators
found 11 cases of new-onset, acute, and severe glucose intolerance after treatment with
clozapine, olanzapine or quetiapine (62). Most worrisome, of these 11 patients, 5
developed diabetic ketoacidosis (62). Interestingly, glucose metabolism was labile in all
of the cases, and 2 of the patients had resolution of glucose intolerance despite continued
treatment with antipsychotics. The authors pointed out that labile glucose intolerance is
typically suggestive of type 1 diabetogenesis (62). They also made the interesting point
that many of the symptoms of diabetes overlap with those of antipsychotic medications,
such as dry mouth, blurry vision, hyperphagia and polyuria, thereby blunting the typical
triggers for patient alarm (62). Therefore, physicians should always consider diabetes in
their differential diagnosis of these common side effects of antipsychotics.
In 2002 Newcomer et al. studied blood glucose levels in 48 schizophrenic patients
on various antipsychotics relative to 31 healthy controls matched for adiposity and age (2,
58). First generation antipsychotics were associated with very small increases in blood
glucose levels after glucose challenge, while the second generation antipsychotics
risperidone, clozpaine and olanzapine were associated with significant increases (58).
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Antipsychotics and Metabolic Syndrome

Syndrome X, later renamed metabolic syndrome, was first described in 1988 by
Gerald Reaven to describe a cluster of risk factors that included hypertension, glucose
intolerance, high triglycerides, and low high-density lipoprotein (HDL) cholesterol (63).
Metabolic syndrome has been defined in numerous ways by various organizations over
the years, but one of the more commonly accepted definitions was published by the
International Diabetes Federation (IDF) in April of 2005 (64). The IDF defined metabolic
syndrome by focusing on central obesity. Their definition required a person to have
central adiposity defined on the basis of waist circumference, and two or more of the
following four factors: elevated concentration of triglycerides, reduced contentration of
HDL cholesterol, elevated blood pressure and dysglycemia (64). According to this
definition, and using US data on adults from the National Health and Nutrition
Examination Survey data from 1999-2002, Ford calculated that nearly 40% of the US
population has metabolic syndrome (64). Using the National Cholesterol Education
Program (NCEP) definition, he calculated the prevalence to be 35% (64).
The metabolic syndrome has been associated with elevated cardiovascular
mortality and morbidity, elevated all-cause mortality, and risk of diabetes (63, 65). Using
the NCEP definition of metabolic syndrome, the relative risk is 1.27 for all-cause
mortality, 1.65 for cardiovascular disease, and 2.99 for diabetes (65). The populationattributable fraction for the metabolic syndrome was 6-7% for all-cause mortality, 1217% for cardiovascular disease, and 30-52% for diabetes (65).
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Lamberti et al. published a cross-sectional study on the prevalence of metabolic
syndrome in 93 schizophrenic outpatients receiving clozapine relative to 2,701
comparison subjects (66). The prevalence of metabolic syndrome was significantly
higher in patients receiving clozapine (53.8%) than among the comparison group (20.7%)
(66). Within the clozapine population, associations were found with age, BMI, and
duration of treatment with clozapine(66). The potentially high rate of metabolic
syndrome in psychotic patients is concerning given that schizophrenia is already
associated with increased cardiovascular mortality (26, 27).

Putative Mechanisms for Antipsychotic-Induced Metabolic Abnormalities and
Molecular Assessment of Metabolic Risk in Patients with Psychotic Disorders

Researchers have offered various explanations for the cause of weight gain and
metabolic disturbance in psychotic patients. None of the evidence is very strong, so most
hypotheses remain rather speculative. Hypotheses have included ideas related to changes
in basal metabolic rate, altered levels of baseline physical activity, alterations in appetite
and satiety, insulin resistance and impaired cellular glucose metabolism.
Mouse models of visceral obesity and certain human studies have suggested an
association between visceral fat and metabolic syndrome, leading some researchers to
believe that the accumulation of visceral fat during antipsychotic use may underlie certain
metabolic consequences of antipsychotic use (67). Mice overexpressing 11-beta
hydroxysteroid dehydrogenase develop visceral fat deposition and other metabolic
abnormalities, suggesting a possible pathomechanism for antipsychotics (67). Visceral fat
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also correlates with insulin resistance, suggesting a possible pathological relationships
where antipsychotics may be involved (68). The hormone resistin may also play a role in
the development of type 2 diabetes (69). Zhang et al. conducted an imaging study in a
sample of 46 patients with first-break psychosis (antipsychotic-naïve) to determine
whether abdominal fat deposition increased after 10 weeks of exposure to an
antipsychotic, primarily risperidone or chlorpromazine (70). It was concluded that,
relative to healthy controls without exposure to antipsychotics, the subjects exposed to
antipsychotics had substantitally increased desposition of subcutaneous and intraabdominal fat (70). In these same patients, levels of leptin, fasting lipids, and non-fasting
glucose were found to be elevated (70). Zhang et al.’s findings may reflect one of the
reasons that waist circumference has been found to be such an effective tool for
determining who is at risk for metabolic syndrome (71).
Certain genes have been associated with the development of metabolic syndrome,
and interaction between these genes and antipsychotics may result in metabolic
aberrations in patients (2). Genes putatively involved in the pathways that determine the
effects of antipsychotics on metabolism include those encoding leptin, the leptin receptor,
the melanocortin 4 receptor, pro-opiomelanocortin, prohormone convertases, Badrenergic receptors in adipose tissue, fatty acid binding protein, lipases, mitochondrial
proteins, and TNF-alpha and glycogen synthase (2).
A monozygotic twin study by Theisen et al. lends credence to the hypothesis that
genetics play an important role in the development of metabolic abnormalities in patients
taking antipsychotics. Theisen’s group found that both twins gained weight after starting
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first-generation antipsychotics and later clozapine, for a total of 38 kg and 40 kg,
respectively, over a 2.5 year period (72).
Zhang et al. found a functional polymorphism -2548G/A in the promoter region
of the leptin gene that was associated with significantly increased weight gain in
antipsychotic-naïve patients exposed to antipsychotics (73).
A prospective study by Basile et al. involving 80 patients treated for
schizophrenia with clozapine found that weight gain at 6 weeks was correlated with
polymorphisms in 9 genes encoding seratonin, histamine, adrenergic receptors,
cytochrome p450 or TNF-alpha (74).
The relationship between weight gain, certain atypical antipsychotics, and
activation of the TNF-alpha system have suggested that the TNF-alpha system may
underlie the relationship between antipsychotics and weight gain (2, 75, 76). TNF-alpha
and soluble TNF receptor levels are increased in obese subjects (2). Clozapine,
olanzapine, amitrypitiline and mirtazapine clearly activate the TNF-alpha system (2, 7779). Drugs that did not cause weight gain, such as haloperidol, paroxetine and
venlavaxine did not influence the TNF-alpha system (2, 78). TNF-alpha system
activation does not appear to be the result of weight gain, because it occurs during the
first week of treatment (2). This has led some researchers to suggest that TNF system
activation might be used as a marker to predict weight gain on an individual basis,
enabling early alterations in drug choice or dosing (2).

Detection and Monitoring of Metabolic Disorders in Psychotic Patients
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The growing evidence of an association between psychotic disorders,
antipsychotic drugs, and metabolic abnormalities raises the important question of how to
best monitor for metabolic disorders in a population with psychotic disorders. In fact,
there are many questions that must be answered with regard to screening in this
population, including both those that must be answered by any healthcare screening
program and those that must be answered in this particular context. For one, there is the
issue of tests. Which tests are superior in terms of sensitivity and specificity? How should
the tradeoff between sensitivity and specificity be managed, that is, which is more
valuable for a particular test? What thresholds should be set for positive and negative
results? How simple should it be to implement the test? What should prompt a clinician
to order a test, that is, what positive predictive value ought to be required? Then there is
the question of what interventions should be provided upon obtaining an abnormal result.
Should interventions be biological, social, psychological, or some combination of the
above? Should they be conducted by consults or by the physician ordering the test?
Finally, related closely to the prior question, there is a health systems question, with
challenges for providers, payors, and patients. Who should monitor metabolic data in the
population of chronically mentally ill? Should it be PCCs, MHCs, or someone else? What
responsibility do psychiatrists have to monitor metabolic data in a patient for whom they
prescribe a drug that has possible metabolic side effects? If touching and examining
patients interferes with certain forms of psychotherapy, should such psychotherapists
abstain from prescribing drugs that require the use of a physical exam to monitor side
effects? These are very real questions that arise in the context of monitoring metabolic
disorders in patients with psychotic disorders, and they offer vivid examples of how
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historical divisions within psychiatry, between psychiatrist-as-physician and psychiatristas-psychotherapist, continue to play out today.
There is evidence in the medicine literature that physicians do not adequately
detect and monitor metabolic abnormalities in the general population. A group at Harvard
studied 55,000 physician visits from 1995 to 1996 and found that only 8.6% of physicians
reported obesity in their patients, despite a national a prevalence of 22.7%, according to
the Third National Health and Nutrition Examination Surveys (NHANTES), 1988-1994
(80). In 2005 Ruser et al. conducted a cross-sectional study of 424 patients cared for by
medicine residents in the Yale Internal Medicine Residency Programs and produced
evidence that internal medicine residents markedly under-recognize and under-treat
overweight and obesity (81). The problem of under-recognition exists not only in the case
of weight, but also in the case of diabetes and other metabolic disorders. For example,
according to the 1999-2002 NHANTES, 30.1% of diabetes in the general population was
undiagnosed (48).
There is also inadequate identification and management of overweight and obesity
in the mentally ill population. Evidence suggests that schizophrenia patients are undertreated for hypertension, dyslipidemia and diabetes (82). Nasrallah et al. used data from
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) to evaluate rates
of non-treatment in schizophrenic patients (82). They found that patients were not treated
at the following rates: 30.2% for diabetes, 62.4% for hypertension, and 88.0% for
dyslipidemia (82). Yet in a study by Srihari et al. at a Community Mental Health Center,
which looked at patients on antipsychotic medications, 13.9% of diabetics in the
schizophrenic population had previously undetected diabetes, which was in contrast to a
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surprisingly higher 30.1% of diabetics who were undiagnosed in the general population
(48). Additionally, a study by Dickerson et al. suggested that patients with schizophrenia
and affective disorders were more likely to report receiving some general medical
services in the past year than the general population, including having visited a general
medical doctor and having a complete physical exam (83).
A study very relevant to this thesis was published in 2005 by Buckley et al. (84).
The investigators collected responses from psychiatrists to a ten-question survey about
clinical practices with regard to metabolic side effects from second-generation
antipsychotics. There were 1,534 targets and 258 responses. Although 86% of
respondents reported altering their prescribing behavior due to the side effect profile of
second-generation antipsychotics, a full 41.7% of respondents stated that they had
difficulty obtaining or were unable to obtain resources for determining waist
circumference (84). Also, 23.3% of respondents stated they had difficulty obtaining or
were unable to obtain resources for determining fasting blood glucose (84). Given that
there is strong evidence that waist circumference and fasting blood glucose are two of the
most effective tests for monitoring metabolic health risks, the data in Buckley et al.’s
study is concerning (71, 85-87). The authors also examined baseline testing. They
defined “frequently testing at baseline” as conducting a test more than 60% of the time
before initiating therapy (84). The following percentage of psychiatrists said that they
ordered the following tests “frequently” prior to initiating antipsychotic therapy: 35%
glucose, 27% lipids, and 6% waist circumference (84). Less than 25% of psychiatrists
obtained a blood pressure measurement “frequently” prior to initiating antipsychotic
therapy (84). For each of the following tests, over 40% of psychiatrists reported that,
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after starting a second generation antipsychotic, they did not routinely obtain the
following tests: waist circumference, glucose, blood pressure, or lipid profile (84). Less
than 25% of psychiatrists took a monthly weight (84). These results suggest that, in the
context of prescribing second-generation antipsychotics, routine monitoring of metabolic
metrics has not become a norm in psychiatry – in contrast to all recommendations from
expert panels to date (85-87). It appears, according to Buckley et al., that “although
clinicians are aware of the emergent side effect profile of second-generation
antipsychotics … the impact of recent guidelines upon actual practice is, at best, modest.
This is an evolving standard of care” (84).
A paper by Motsinger et al. reviewed pharmacy data from a community health
center over a 6-month period for patients prescribed atypical antipsychotics (88). They
found that 13% of patients prescribed atypical antipsychotics had fasting blood sugar
levels and 30% had lipid panels measured during the six month study period (88).
Psychiatrists ordered tests at the lowest rates, and physicians trained in primary care plus
psychiatry ordered such tests at the highest rates (88).
In terms of cost effective screening for metabolic syndrome, Straker et al.
produced evidence suggesting that abdominal obesity was most sensitive, at 92%, while
fasting glucose was most specific, at 95.2%, for identifying the presence of metabolic
syndrome (85). Combining abdominal obesity and elevated fasting blood glucose had
100% sensitivity (85). They concluded that measuring abdominal obesity via weight
circumference and fasting blood glucose was a simple and cost-effective means of
screening for metabolic syndrome (85).

25
A group in Canada, Ardern et al., determined that waist circumference (WC) was
an effective tool for detecting metabolic syndrome in women with elevated BMI, but not
in men (89). Janssen et al. found that WC cutoffs helped to identify increased health risk
within all weight categories, including normal (71). The health risks that they reviewed
included hypertension, diabetes, dyslipidemia and the metabolic syndrome (71).
Marder et al. published recommendations for physical health monitoring of
patients with schizophrenia (86). The paper was a direct result of a conference at Mount
Sinai School of Medicine in New York that had focused on the topic (86, 87). The
authors suggested (1) clinics be capable of weighing patients; (2) patients should be
encouraged to track their own weight; (3) BMI monitoring should be supplemented by
waist circumference recording; (4) patients should be weighed at every visit for the first 6
months of treatment or after a medication change (86). The authors also believed that a
gain of 1 unit BMI, or a waist circumference of 35 inches for women and of 40 inches for
men, indicates the need for an intervention (86). In addition, the authors determined that a
BMI over 25 should be cause for considering the relative risks of weight gain posed by
different antipsychotics (86). They emphasized that clinicians should make an effort to
recognize weight gain early to prevent weight gain and obesity, as reversal of these
phenomena is extremely difficult (86).
With regard to diabetes monitoring, the Marder/Mount Sinai group had further
recommendations. They suggested obtaining an initial fasting plasma glucose level
before starting any new antipsychotic, with HbA1c as a secondary option (86). They
recommended further testing of fasting glucose or HbA1c every 4 months if patients
possess significant risk factors for diabetes (based on family history, BMI and waist
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circumference) or if the patient gains weight during antipsychotic treatment (86).
Providers should inform and ask patients about diabetes symptoms such as polydipsia,
polyuria and weight change (86).
The Marder/Mount Sinai group also had recommendations regarding lipid
monitoring (86). They suggested that all patients with schizophrenia should have a lipid
panel performed, including total cholesterol, LDL, HDL, and triglycerides (86). If LDL is
normal, it should be re-tested every 2 years, but if it is above 130 mg/dl, it should be
tested every 6 months (86). Mental health practitioners should identify patients who
fulfill the criteria for metabolic syndrome and should consider all patients with
schizophrenia at risk for coronary artery disease (86).
An article in the British literature recommends an even more aggressive initial
evaluation and early monitoring of metabolic metrics in schizophrenic patients. For
example, they suggest obtaining monthly weights (90).
A 2006 review by Cohn et al. (91) points out that there is a dearth of literature
about the cost-effectiveness of metabolic monitoring of patients taking antipsychotics
(91). Also, Cohn et al. suggested that although psychiatrists do not have the obligation of
becoming experts at the diagnosis and treatment of disorders such as obesity,
hypertension, heart disease and diabetes, they do carry responsibility for delegating
responsibility to qualified experts when appropriate (91).
Using a randomized controlled trial method, Druss et al. looked at organizational
structures and the effectiveness of novel structures relative to standards (92). They
contrasted outcomes in an integrated care system at the Veterans Affairs medical system,
where psychiatric services were integrated with medical services, with the status quo. By
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integrating care, they found psychiatric patients were more likely to visit a primary care
physician and had a greater mean number of visits to a primary care clinician (92). They
also determined that patients had significantly improved general health as measured by
the 36-item Short-Form Health Survey (92). Although general health improved, there was
no improvement in mental health (92). Importantly for healthcare administrators, the cost
of the two systems was equivalent (92). This system is in fact that one at which the data
for this thesis was collected.

STATEMENT OF PURPOSE

We are at an interesting point in the history of psychiatry in which crucial
questions are emerging about the role and responsibility of psychiatrists and other mental
health clinicians (MHCs) in monitoring, reporting, and managing the medical illness of
their patients, as well as the medical side-effects of prescribed psychiatric medications.
The emergence of powerful biological treatments for psychiatric disorders, along with an
increased awareness by clinicians of the medical and biological dimensions of psychiatric
illness, has led to a gradual closing of the historical schism that existed between
psychiatry and the rest of medicine since the beginning of the psychoanalytic era. This
thesis aims to contribute productively to the discussion about the role MHCs currently
play in monitoring a potentially life threatening medical side-effect of second generation
antipsychotic medications. We ask this key question: How do MHCs and primary care
clinicians (PCCs) currently monitor, report and manage the metabolic status of patients
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with psychotic disorders? In answering that question, we will attempt to answer a second
key question: should the status quo change and if so, how?
The scientific means for answering our first key question is to put forth a
hypothesis and then test it with empirical data. Our null hypothesis is that there is no
difference in the rates of monitoring, identifying and intervening for metabolic
abnormalities by MHCs and PCCs at the Veteran’s Affairs facilities in West Haven,
Connecticut. Should we reject the null hypothesis, we secondarily hypothesize that
MHCs monitor, report and intervene for metabolic abnormalities in their patients at rates
that are significantly lower than those of PCCs, and that such rates are too low. The
results of our hypothesis testing will enable us to put forth an answer to our second key
question, which was whether the status quo should change and if so, how.

MATERIALS AND METHODS

Study Overview

We performed a cross-sectional medical record review of overweight and obese
patients with psychotic disorders at the Mental Hygiene Clinic at the West Haven
Campus of the Veterans Affairs Connecticut Healthcare System (VACHS). The study
was approved by the VACHS Human Investigations Committee. As data was extracted
from medical records, it was de-identified in order to protect the privacy of subjects.

Inclusion Criteria
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We searched the VACHS electronic medical record database for patients who met
the following inclusion criteria: (1) primary diagnosis of schizophrenia or schizoaffective
disorder (from DSM-IV, International Classification of Disease codes 295.10, 295.30,
295.60, 295.70, and 295.80); (2) at least one routine mental health visit at the West
Haven VA facility (VA stop codes 502, 552 and 576) between July 1, 2005 and June 30,
2006; and (3) overweight or obese, as determined by a body mass index (BMI) > 25. We
excluded all deaths. After identifying subjects who met all of our selection criteria, we
had a remaining cohort of 123 subjects.

Data Extraction Methods

We parsed the electronic medical records of subjects in the cohort and extracted
relevant data from July 1, 2005 through June 30, 2006. Data was first recorded on
standardized paper sheets (see Appendix) and then entered into Microsoft Excel
spreadsheets. For each subject, we examined general patient background data, primary
care clinician (PCC) visit notes, and mental health clinician (MHC) visit notes. We only
examined data from routine outpatient visits, ignoring emergency room visits and
hospitalizations.
Two psychiatrists, one primary care physician, and one medical student extracted
data from the medical records. In order to develop a standardized process for extracting
and recording data, and so as to decrease inter-rater variability, all raters reviewed the
same charts for four weeks and compared results on a weekly basis. Changes to the data
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extraction form and discussions about the process improved the subsequent
standardization of data collection.
We extracted data regarding age, sex, race/ethnicity, weight, BMI, alcohol and
tobacco use, co-morbidities, antipsychotic treatment, number of PCC visits, and number
of MHC visits. Co-morbidities extracted from the past medical history section of notes
included diabetes type 1, diabetes type 2, hypertension, hypercholesterolemia,
dyslipidemia, osteoarthritis or degenerative joint disease, obstructive sleep apnea,
hyperthyroidism, metabolic syndrome, and coronary artery disease. We examined
clinician notes for documentation of the following information: waist size, weight, height,
and BMI. We recorded identifications of weight in the problem list, history of present
illness, or assessment and plan of clinician notes. We recorded whether clinicians
identified a linkage between weight and antipsychotics and whether they recommended
weight loss as a therapy for a diagnosis other than obesity. We also recorded whether
clinicians documented ordering any of the following laboratory tests in their notes: blood
glucose, thyroid stimulating hormone (TSH), urinalysis, lipid panel, or hemoglobin A1C.
Finally, we recorded instances when interventions related to weight management
were documented in clinician notes. We determined whether a weight-related referral was
made for a nutrition/dietician, physical therapist, behavioral modification clinic, social
worker, endocrinologist, surgeon or other consultant. We recorded whether the clinician
made

dietary

or

exercise

recommendations.

We

also

determined

whether

pharmacotherapy for weight loss was considered or ordered, and whether a change in
antipsychotic medication or dose considered or ordered as a result of weight issues.
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Statistical Methods

After collecting all the data, we analyzed it in Microsoft Excel. For continuous
variables such as weight, we calculated descriptive statistics such as mean, median,
mode, range, minimum, maximum, and standard deviation. For discrete variables
characterized by either a positive or negative value, we calculated sample proportions.
For any given variable there were two samples, one from primary care and one from
mental health, so it was necessary to compare the sample proportions from these two
groups in order to determine whether the clinician groups acted differently. Towards that
end, we calculated 95% confidence intervals for the difference in sample proportions (see
equation below). (All confidence intervals reported in this thesis can be assumed to be
95% confidence intervals for the difference in two proportions.) If the confidence interval
did not cross zero, the difference was deemed statistically significant. We also calculated
a p-value for the difference in sample proportions by setting the lower bound of the
confidence interval equal to zero, determining the subsequent z-score, and thereby
finding the p-value.

)

)

CI = π 1 − π 2 ± Zα / 2

)

)

π 1(1 − π 1)
n1

+

)

)

π 2(1 − π 2)
n2
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RESULTS

(Note: All tables are displayed in the text body but have also been consolidated in
the Appendix.)
As displayed in Table 1, we found that in our population of 123 subjects, a
majority of subjects were white (56%). African-Americans (21%) and Not Documented
(20%) comprised significant minorities. Only 2% of subjects were Hispanic. As shown in
Table 2, our subjects were predominantly male (93%), and the remaining only 7% were
documented as female.
Table 1: Subject Race/Ethnicity (N=123)
Percent
Not Documented

20%

White

56%

Hispanic

2%

African-American

21%

Other

1%

Table 2: Subject Gender (N=123)
Percent
Male
Female

93%
7%
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Statistics regarding the age, weight, BMI and number of routine office visits by
subjects are presented in Table 3. The mean age of subjects was 54 years (SD=8 years).
Subjects were overweight or obese: the mean weight was 218 pounds (SD=25 pounds)
and the mean BMI was 32.4 (SD=5.4). Subjects visited mental health providers more
often than primary care providers. The mean number of PCC office visits was 3.4 visits
(SD=4.0 visits); the mode was lower at 2.0 visits. The mean number of MHC visits was
15.6 (SD= 11.1 visits); the mode was lower at 12 visits.
Table 3: Age, Weight, BMI, and Number of Routine Office Visits (N=123)
Number of Routine
Visits
AGE

WEIGHT

Primary

Mental

(years)

(pounds)

BMI

Care

Health

Mean

54

218

32.4

3.4

15.6

Median

54

215

31.3

2.0

12.0

Mode

54

233

31.7

2.0

12.0

Minimum

31

137

25.0

1.0

1.0

Maximum

85

312

50.5

41.0

59.0

Range

54

175

25.5

40.0

58.0

8

35

5.4

4.0

11.1

Standard
Deviation

Table 4 displays data on alcohol and tobacco use, as well as the co-morbidities
that were extracted from the past medical history data found in clinician notes. In our
sample, 51% of subjects were tobacco smokers. The most prevalent co-morbidities were
the following: type 2 diabetes (23%); hypertension (57%); hypercholesterolemia (30%);
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and dyslipidemia (40%). 10% of subjects carried diagnoses of diabetes, hypertension and
dyslipidemia, thus meeting the criteria for metabolic syndrome – and yet there was not a
single diagnosis of metabolic syndrome in the entire sample. The prevalence of coronary
artery disease was 9%.
Table 4: Subject Co-morbidities (N=123)
Percent
Diabetes Type I

1%

Diabetes Type II

23%

Hypertension

57%

Hypercholesterolemia

30%

Dyslipidemia

40%

Osteoarthritis; Degenerative
Joint Disease

19%

Obstructive Sleep Apnea

10%

Hypothyroidism

5%

Metabolic Syndrome

0%

Coronary Artery Disease

9%

Any Smoking (current)

51%

Any Alcohol Use (current)

21%

High Alcohol Use (current)
(women >7 drinks per week;
men >14 drinks per week)

9%

Table 5 shows data about the rates of antipsychotic treatment in the sample
population, as determined from clinician notes. We found that 37% of subjects were
prescribed a first-generation antipsychotic, 85% were prescribed a second-generation
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antipsychotic, 97% were prescribed at least one antipsychotic of any type, and 25% were
prescribed both a first-generation and a second-generation antipsychotic. The following
percentage of subjects were prescribed particular second-generation antipsychotics: 10%
aripiprazole (Abilify); 11% clozapine (Clozaril); 22% olanzapine (Zyprexa); 24%
quetiapine (Seroquel); 29% risperidone (Risperdal); and 8% ziprasidone (Geodon).
Table 5: Rates of Antipsychotic Therapy (N=123)
Percent
Prescribed First Generation Antipsychotic

37%

Prescribed Second Generation Antipsychotic

85%

Prescribed at Least One Antipsychotic of
Any Type

97%

Prescribed Both a First and Second
Generation Antipsychotic

25%

Aripiprazole (Abilify)

10%

Clozapine (Clozaril)

11%

Olanzapine (Zyprexa)

22%

Quetiapine (Seroquel)

24%

Risperidone (Risperdal)

29%

Ziprasidone (Geodon)

8%

Table 6 shows the rates at which PCCs and MHCs documented weight-related
biometrics. In the sample population, not a single subject had their waist-size documented
by a PCC or MHC. Waist-size is a fundamental biometric used for assessing risks
associated with metabolic syndrome. Far more subjects had their weight documented by
PCCs than by MHCs (85% vs. 11%; CI 0.66-0.82; p<0.001). The same was true for
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documentation of BMI (48% vs. 0%; CI 0.39-0.57; p<0.001). It is notable that MHCs
also failed to document BMI in any subjects.
Table 6: Documentation of Biometrics in Visit Notes (N=123)
95% CI

Waist size

Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

0%

0%

-

-

-

Weight

85%

11%

0.66

0.82

<0.001

Height

59%

2%

0.48

0.66

<0.001

BMI

48%

0%

0.39

0.57

<0.001

Table 7 displays the rates at which PCCs and MHCs identified weight as an issue
in their notes. PCCs identified the issue of weight more often than MHCs (45% vs. 28%;
CI 0.04-0.28; p<0.005). PCCs were also far more likely than MHCs to mention weight
loss as a therapy for a diagnosis other than obesity (28% vs. 4%; CI 0.15-0.32; p<0.001).
PCCs and MHCs rarely identified the link between antipsychotics and weight issues in
their notes (10% vs. 12%; not a statistically significant difference).
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Table 7: Identification of Weight Issues Documented in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

28%

13%

0.06

0.25

<0.005

26%

15%

0.01

0.21

<0.015

39%

17%

0.11

0.33

<0.001

45%

28%

0.04

0.28

<0.005

10%

12%

-0.10

0.05

0.730

28%

4%

0.15

0.32

<0.001

Identified weight as an issue in
problem list
Identified weight as an issue in
history
Identified weight as an issue in
assessment and plan
Identified weight as an issue in
at least one of the following:
problem list; history; assessment
and plan
Identified link between weight
and antipsychotics
Identified weight loss as a
therapy for a diagnosis other
than obesity

As shown in Table 8, PCCs ordered laboratory tests that can identify metabolic
abnormalities far more often than MHCs did. For every test, including blood glucose,
thyroid stimulating hormone, urinalysis, lipid panel, and hemoglobin A1C, there was a
large and statistically significant difference between the proportion of subjects that were
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ordered tests by PCCs versus by MHCs. For example, PCCs ordered a blood glucose for
50% of subjects and MHCs only did so for 4% of subjects (CI 0.36-0.55; p<0.001).
Table 8: Tests Ordered in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

Blood glucose

50%

4%

0.36

0.55

<0.001

TSH

15%

4%

0.04

0.19

<0.005

Urinalysis

14%

0%

0.08

0.20

<0.001

Lipid panel

71%

2%

0.61

0.77

<0.001

Hemoglobin A1C

25%

2%

0.16

0.32

<0.001

Table 9 shows the weight-management interventions that were documented by
PCCs and MHCs. PCCs were more likely than MHCs to make dietary and exercise
recommendations to subjects (42% vs. 19%; CI 0.12-0.35; p<0.001) and they were also
more likely to order a weight-management referral (21% vs. 3%; CI 0.10-0.26; p<0.001).
Although MHCs were more likely than PCCs to order or to consider ordering a change of
antipsychotic medication or dose due to weight-related issues (6% vs. 3%), the difference
was not statistically significant. The low rates at which clinicians considered altering
antipsychotic prescriptions for weight-related reasons is echoed by the low rates at which
they linked weight issues to antipsychotic treatment in their notes (see Table 7).
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Table 9: Interventions For Weight Loss Documented in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

Made dietary recommendations to
patient

57%

25%

0.20

0.43

<0.001

46%

22%

0.12

0.35

<0.001

42%

19%

0.12

0.35

<0.001

21%

3%

0.10

0.26

<0.001

1%

0%

-0.01

0.02

0.158

2%

4%

-0.06

0.03

0.764

2%

5%

-0.07

0.02

0.846

3%

6%

-0.08

0.03

0.823

Made exercise recommendations to
patient
Made exercise and dietary
recommendations to patient
Ordered at least one referral for weight
management
Considered or ordered
pharmacotherapy for weight loss
Considered or ordered change of
antipsychotic medication due to weight
Considered or ordered change of
antipsychotic dose due to weight
Considered or ordered change of
antipsychotic medication and/or dose
due to weight
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DISCUSSION

In order to better understand how mental health clinicians (MHCs) and primary
care clinicians (PCCs) identify, monitor and intervene for metabolic disorders in patients
with psychotic disorders, we studied the medical records of 123 overweight or obese
veterans (BMI ≥ 25) with psychotic disorders at the Veteran Affairs outpatient facilities
in West Haven, Connecticut during a one year period from July 1, 2005 to June 30, 2006.
Our subjects were predominantly white and male (56% and 93%, respectively), with an
average age of 54 years (SD=8 years). The subjects had an average weight of 218 pounds
(SD=35 pounds) and an average body mass index (BMI) of 32.4 (SD=5.4). We found that
97% of subjects were taking an antipsychotic of some sort, and 85% were taking a
second-generation antipsychotic – the category most frequently associated with metabolic
side effects. The most frequently prescribed second-generation antipsychotics were
risperidone (29%), quetiapine (24%), and olanzapine (22%), all of which have been
associated with metabolic side-effects in the medical literature – particularly risperidone
and olanzapine (see Introduction for details). In general, we found that, despite far more
average annual visits to MHCs than PCCs (15.6 visits vs. 3.4 visits), PCCs were much
more likely than MHCs to identify, monitor and treat a variety of weight and metabolic
parameters in our study population over the course of a year.
Our results have led us to reject the null hypothesis that there is no difference in
the rates of monitoring, identifying and intervening for metabolic disorders by MHCs and
PCCs at the Veteran’s Affairs facilities in West Haven, Connecticut. We also accept our
secondary hypothesis, which is that MHCs monitor, report and manage metabolic
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abnormalities in their patients at rates that are significantly lower than those of PCCs. We
will discuss the evidence leading to these conclusions in the subsequent sections of this
Discussion.

Documentation of Biometrics by Clinicians

MHCs documented weight-related biometrics at extremely low rates, both
absolutely and relative to PCCs. During the one-year study period, MHCs documented
weight measurements for only 11% of subjects, whereas PCCs documented weight
measurements for 85% of subjects (CI 0.66-0.82; p<0.001). Similarly, MHCs
documented BMI for 0% of subjects, whereas PCCs documented BMI for 48% of
subjects (CI 0.39-0.57; p<0.001). Our findings are concerning because they suggest that
PCCs were seven to eight times more attentive to measurements of weight than MHCs,
despite the fact that 97% of subjects in the study were prescribed antipsychotics by
MHCs. A possible explanation for the disparity between clinician groups is that MHCs
might expect PCCs to monitor the weight-related side effects of the antipsychotics that
MHCs prescribe. Also, MHCs may not have the resources to perform weight monitoring,
such as scales and support staff. That being said, even if MHCs do rely upon PCCs to
perform all metabolic monitoring, such an expectation should be explicit and the results
from primary care consultations and follow-up should be documented clearly in mental
health visit notes.

Diagnosis and Monitoring of Metabolic Syndrome by Clinicians
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It is concerning that, although our subjects carried significant rates of diagnoses
that are associated with metabolic syndrome, including 23% type 2 diabetes, 55%
hypertension, and 38% dyslipidemia ―10% of subjects carried all three diagnoses―,
there was not a single clinician that identified a subject as having metabolic syndrome. It
seems highly unlikely that, in the setting of such co-morbidities, there was truly a 0%
prevalence of metabolic syndrome in the cohort. Moreover, given that the literature
suggests that the general prevalence of metabolic syndrome in the United States may be
as high as 40%, clinicians in our study were likely significantly under-diagnosing
metabolic syndrome (64). We also determined that zero subjects were measured for a
waist-circumference by a PCC or MHC during the study period. This too is alarming,
given that the literature has deemed waist circumference to be one of the most valuable
metrics for diagnosing metabolic syndrome risk and for assessing associated health risks
(see Introduction for details) (71, 85). Our results indicate that the level of clinician
awareness about metabolic syndrome, and the rate at which it is diagnosed and followed
by PCCs and MHCs, may be grossly inadequate. Given the morbidity associated with
metabolic syndrome, and the baseline cardiovascular risks associated with schizophrenia
(26, 27), our findings suggests that subjects in our study may face significantly greater
health risks if the quality of monitoring is not improved.

Identification and Interpretation of Weight Issues by Clinicians
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We examined the rate at which clinicians listed weight as an issue in certain key
sections of the visit note, including the problem list, the past medical history, and the
assessment and plan. When we evaluated how often clinicians identified weight as an
issue in at least one of these sections of the visit note, the difference between groups was
significant: PCCs identified weight as an issue in 45% of subjects, whereas MHCs
identified it in only 28% of subjects (CI 0.11-0.33; p<0.005). Thus weight does not
appear to be a standard issue addressed by clinicians in patients who are overweight or
obese.
We also found that both MHCs and PCCs infrequently identified the link between
antipsychotics and weight gain in their notes (10% vs. 12%; not a statistically significant
difference). Given the extensive literature linking antipsychotics to weight gain, which
we discussed in the Introduction, the fact that all of the subjects in our study were
overweight or obese, and the fact that almost all subjects were taking an antipsychotic,
clinicians should have remarked on this linkage more frequently in their notes. The
failure to identify the link between antipsychotics and weight was echoed by the low rates
at which PCCs and MHCs ordered or considered ordering adjustments to antipsychotic
prescriptions due to metabolic side-effects (3% and 6%, respectively; not a statistically
significant

difference).

It

is

surprising

that,

despite

MHCs’

expertise

in

psychopharmacology and their role as the primary prescribers of antipsychotics in our
study sample, they did not significantly outperform PCCs on criteria of linkage or
prescription change.
Interestingly, PCCs were also much more likely than MHCs to recommend
weight loss for a diagnosis other than obesity (28% versus 4%; CI 0.15-0.32; p<0.001).
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This reveals that, at least as understood by their documenting habits, PCCs displayed a
greater awareness of the health benefits offered by weight loss beyond merely loss of
weight (e.g. lower triglycerides and lower blood pressure). Given that PCCs are tasked
with monitoring and treating a much wider range of medical conditions than MHCs (e.g.
diabetes and heart disease), it makes sense that they would be more attuned to, and
concerned about, how weight issues interact with non-psychiatric disease processes. At
the same time, given that the schizophrenic psychiatric population faces increased risks
for several co-morbid medical diseases and conditions (26, 27, 93), MHCs should be
attentive to those risks and how they are monitored.

Laboratory Testing and Intervention by Clinicians

On almost every dimension of laboratory testing or intervention that we studied in
clinician notes, PCCs were more interventionalist than MHCs. According to their notes,
PCCs ordered all of the following tests at higher rates than MHCs: glucose (ordered for
50% versus 4% of subjects; CI 0.36-0.55; p<0.001); thyroid stimulating hormone (15%
versus 4%; CI 0.04-0.19; p<0.005); urinalysis (14% versus 0%; CI 0.08-0.20; p<0.001),
lipid panel (71% versus 2%; CI 0.61-0.77; p<0.001); and hemoglobin A1c (25% versus
2%; CI 0.16-0.32; p<0.001). In terms of interventions, PCCs documented ordering at
least one referral for weight or metabolic-related concerns for 21% of subjects, whereas
MHCs only did so for 3% of subjects (CI 0.10-0.26; p<0.001). In terms of counseling,
PCCs counseled 42% of subjects on both diet and exercise, while MHCs only did so for
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19% of subjects (CI 0.12-0.35; p<0.001). Additionally, only one PCC – and not a single
MHC – mentioned pharmacotherapy for weight loss in their note.
As mentioned earlier, rates of recommending a change of antipsychotic drug or
dose were very low among both PCCs and MHCs (3% vs. 6%; not a statistically
significant difference). This was surprising, given that the literature has documented that
different antipsychotics carry different metabolic risk profiles, and hence patients who
experience metabolic side-effects from one antipsychotic may benefit from a change to
another drug or a lower dose (see Introduction for details). Our data suggests that MHCs
may be focusing primarily on the management of psychiatric symptoms without devoting
sufficient attention to the management of drug side-effects.

Study Limitations

Since our study focused exclusively on veterans who receive their care within a
single healthcare system, it is difficult to extrapolate the results to other settings, such as
private practice psychiatry, prisons, or other state-funded medical centers. Also, one of
the primary care clinics at the West Haven VA, where we conducted our study, is in the
same building as a mental health clinic and focuses specifically on patients with severe
mental illness. This sort of integration and communication between primary care and
mental health is not standard in the nation. One would suspect that this model actually
enhances both PCC and MHC awareness about the metabolic side-effects of
antipsychotics, and thus that more disjoined healthcare delivery systems would perform
even worse.
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It is worth noting that the PCCs and MHCs who cared for the subjects in our
study had varying levels of professional education and expertise. For example, PCCs
were predominantly attending physicians, resident physicians, and advanced practice
registered nurses (APRNs), whereas MHCs included a broad mixture of attending
physicians, resident physicians, APRNs, registered nurses (RNs), psychologists, and
social workers (although 93% had contact with an attending physician, resident
physician, or APRN during the study period). It is not clear how this diversity of
caregivers affected rates of identification, monitoring and treatment in the PCC and MHC
groups.
Our study is also limited by the fact that we primarily gathered clinical data from
clinician notes, rather than from laboratory transactions or directly observed behavior.
The focus on documentation could have led to a biased representation of actual clinician
behaviors. First, if the culture and attitudes that inform MHCs’ documentation habits
differ significantly from those of PCCs, then the two groups could have systematic
differences in documentation outputs. For example, it might be the case that PCCs writeup their blood glucose orders in notes more regularly than MHCs, even though the two
groups might actually request blood glucose orders at identical rates. Likewise, MHCs
and PCCs might identify weight as an issue and counsel patients on diet and exercise at
equal rates, but they might document such findings and actions differently. If these types
of systematic documentation differences exist between groups, then our study would
reveal more about communication and the documentation of behaviors than it would
about the behaviors themselves. Future studies could actually evaluate documentation
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differences by comparing documentation in notes to laboratory orders or observed
behaviors.
Aside from systematic inter-group documentation biases, there may also be
general documentation issues affecting our study. It is likely that clinicians only
document a limited sample of the behaviors that they actually perform, and similarly, that
they only document a limited sample of the clinical knowledge that they generate. Thus
documentation rates may appear much lower than one would expect. A good example of
this might be coronary artery disease: if clinicians did not document the condition, then
we did not see it in the past medical history, and so the rates of coronary artery disease
may have appeared low – even if clinicians were aware of and treating the condition.
Another documentation issue that may have impacted our study results is that
PCCs may have issued the orders that we examined for reasons unrelated to
antipsychotics or metabolic issues (e.g. ordering a urinalysis to assess urinary tract
infection symptoms). This activity may have muddled our comparisons between PCCs
and MHCs on the basis of tests ordered, because MHCs are responsible for identifying
and treating a more limited panel of non-psychiatric diseases than PCCs.
We used three physicians and one medical student to analyze the medical records
and this raises the possibility that there was inter-rater variability. In addition, there may
have been intra-rater variability, considering the large amount of note material that we
were evaluating. For example, there is a certain degree of subjectivity in determining
whether a clinician has definitively “identified a link between weight and antipsychotics
as an issue” in his or her note, and a rater’s analysis may vary for a given rater or between
raters depending on the material and context in any given note. To counteract bias, all of
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the raters gathered on a regular basis to compare approaches and to discuss ambiguous
cases. Furthermore, during the first four weeks of analysis the group met weekly to
discuss a set of comparison cases thereby helping to standardize data collection methods.
Our study looked at collective rates of identification, monitoring and treatment
across a one-year period, yet this may have masked the disparities that exist on a per-note
basis. For example, “identified weight as an issue” was marked a positive “yes” if it
occurred at least once in a clinician note during the one-year period. So there could have
been many positives among either many or few notes during the year, or a single positive
among either many or few notes. In all of these cases the outcome would be the same: a
positive “yes.” This phenomenon of ambiguity could also occur in the case of negatives.
If the data had been examined on a per-note basis, we may have found either an
amplification or diminution of differences between PCCs and MHCs. Our suspicion is
that, since the average number of MHC visits in our study was much higher than the
number of PCC visits (15.6 visits vs. 3.4 visits), the differences would in fact be
amplified, lending further evidence to support our finding that, relative to MHCs, PCCs
more aggressively identify, monitor and treat metabolic dysfunction in patients with
psychotic disorders.

General Implications of Study Results

MHCs often prescribe antipsychotics that cause metabolic side-effects to patients
with psychotic disorders, and yet our study has shown that they infrequently monitor such
side-effects. These results bring objective evidence to support the more subjective results
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that were reported in Buckley et al.’s survey of physicians, from which the researchers
concluded, “Although clinicians are aware of the emergent side-effect profile of secondgeneration antipsychotics … the impact of recent guidelines upon actual practice is, at
best, modest. This is an evolving standard of care” (84). Our results also show that
patients suffering from psychosis interact more frequently with MHCs than PCCs, and in
the general community many psychotic patients probably do not regularly see PCCs. This
creates a situation that allows patients who develop side-effects to fall systematically
through the cracks of the “monitoring system” (if such a system could accurately be said
to exist). It seems that MHCs should be charged with the primary responsibility to
monitor the side-effects of the drugs they prescribe. Just as MHCs are professionally
responsible for monitoring for agranulocytopenia in patients who take clozapine, MHCs
should also be responsible for monitoring for metabolic side-effects in patients who take
antipsychotics, particularly second-generation antipsychotics. Indeed, MHCs should be
identifying and monitoring patients with metabolic disorders for a variety of reasons: (1)
MHCs prescribe the antipsychotics that cause metabolic side-effects; (2) MHCs see their
patients more often than PCCs; (3) patients without access to PCCs may still access
MHCs; (4) MHCs often understand patients’ biopsychosocial context better other
clinicians; and (5) MHCs often have very strong relationships and interpersonal leverage
with their patients. Relative to the Mount Sinai Conference guidelines regarding
monitoring for the metabolic side-effects of antipsychotics, which we discussed in detail
in the Introduction, the MHC system in our study, and perhaps nationally too, is
underperforming (86, 87). Rather than describing this situation as an “evolving standard
of care,” in the words of Buckley et al., we believe it might be more accurately described
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as a “dangerous failure in quality control.” Indeed, undetected metabolic side-effects
from atypical antipsychotics can be life-threatening. This story is yet another example of
the serious quality control problems that are rampant in American healthcare. Quality
control systems in American healthcare are abysmal when compared to those of
industries such as the airline industry or of companies such as Toyota.
After MHCs identify patients with develop metabolic side-effects, the subsequent
step is either to manage the issue themselves or to obtain a consultation from a specialist
who can do so. Our study suggests that neither active management of side-effects nor the
consultation of specialists is happening adequately today.
There is no value in merely pointing fingers or allocating blame for what is
without question a system-wide failure of quality control. Instead, efforts must be made
by leadership at both the local and national level to introduce systemic reforms that will
ensure that all patients will be appropriately monitored and treated for the metabolic sideeffects of antipsychotics.
Briefly, we might gain some insight on today’s quality-control problem by
speculating about its historical origins. It is not unreasonable to suspect that today’s
problem began with the historical separation of psychiatry and the rest of medicine. In the
past, both the lack of biological treatments for psychiatric disorders and the dominance of
psychoanalytic practice, in which the patient’s body was rarely if ever touched, led the
daily routines of psychiatry to diverge from the rest of medicine. Metaphorically, the
stethoscope was put aside and replaced by the couch. But since the advent and
proliferation of biological treatments, such as antipsychotics, those routines have needed
to change and become reacquainted with the rest of medicine. Nevertheless, it seems as
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though the historical residue indeed persists, leaving us with a psychiatric approach to
patient care, and a system of mental health, that continues to focus insufficient attention
on the body relative to the mind.

Options for a Local Response to Study Results

If the implications of our findings are interpreted narrowly, so as to apply only
locally, then we should examine what our findings mean for the West Haven VA. Clearly
the metabolic parameters of patients on second-generation antipsychotics are not being
adequately followed by MHCs at the West Haven VA, and this is systemic quality
failure. Thus system reform is critical. Six solution frameworks can be used to quickly
address the quality failure: (1) establish quality goals and objectives; (2) appoint
leadership; (3) educate; (4) allocate resources; (5) facilitate dialogue; and perhaps most
importantly, (6) standardize work processes.
Within each of these six frameworks, there are some very direct steps that the
West Haven VA could take to have rapid impact. Quality improvement could be declared
a goal, supported by explicit and measurable objectives. A leader could be appointed to
coordinate and monitor the organization’s drive toward quality improvement. This leader
should be familiar with the tools and concepts of quality management (94-98). In terms
of education, sending a letter to all MHCs regarding the findings of this study, along with
a copy the Mount Sinai guidelines, would be one way to initiate an awareness campaign.
Our findings and the Mount Sinai guidelines could be presented at a mental health staff
meeting or mental health grand rounds. Also, the Mount Sinai guidelines could be posted
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in the mental health clinics as a reminder to staff about the importance of monitoring for
metabolic disorders, and information about the weight and diabetes management referral
resources that are available to clinicians at the VA could be consolidated and
disseminated to providers. In terms of resource allocation, leadership would need to first
determine what resources are already in place, followed by the deployment of budgetary
resources and personnel to address gaps (e.g. lack of scales, measuring tapes, or technical
staff). Regarding facilitating a dialogue, gatherings could be organized to bring together
clinicians from different areas of the West Haven VA provider community in order to
discuss ways to improve the management of metabolic disorders within the network.
Finally, in order to standardize processes, management at the West Haven VA could put
in place a clinical reminder that “pops up” in the electronic medical record of overweight
or obese patients who take antipsychotics. This would remind MHCs to evaluate the
weight and other metabolic parameters of such patients. By standardizing the work
process in this way, variance in clinician behavior would drop and quality of care would
subsequently improve.
Another issue to address is that of process standards for documentation and notes
within the electronic medical records, which is a more general problem throughout the
VA healthcare system. Anecdotally, those familiar with the VA system will often
comment on the problem of clinicians copying and pasting notes, and the problem of
casually written notes that possess inadequate relevant information. The concern is that
there is too little relevant information and too much irrelevant information in the system –
the signal to noise ratio is low. We encountered this problem repeatedly during our study.
Poor documentation ultimately obfuscates critical information and systematically impairs
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communication, thereby adversely affecting the quality of patient care throughout the
system. Policies, incentives and better workflow designs need to be implemented at the
VA to resolve the problem, perhaps on a hospital or even nation-wide basis.

Options for a National Response to Study Results

If the implications of our findings are interpreted more broadly, that is if we
consider them as potentially representative of a phenomenon occurring on a national level
rather than simply at the level of the West Haven VA, then we must address a vast and
complex problem. In fact, the situation may be much worse for patients on a national
level than it was in our study. For one, the West Haven VA is affiliated with the Yale
academic medical network, so one might assume that the clinicians there are more up-todate on the current standards of care than clinicians at non-academic sites around nation.
Also, the VA system offers relatively integrated and well-coordinated care, especially at
the West Haven VA, where there is a primary care clinic devoted exclusively to patients
with severe mental illnesses. But outside of the VA, mental healthcare in the US is often
isolated from the rest of medicine. This makes the consultation process a challenge and
may limit patient access to primary care physicians who monitor metabolic parameters.
For example, community nephrologists, cardiologists, and renal transplant surgeons
communicate regularly, but community psychiatrists are often outside of such quotidian
communication and referral loops. Our study raises the question of whether this status
quo should change. Indeed, psychiatrists are physicians first and psychiatrists second,
working within the medical model of care, and so more effort should be brought to
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integrate them with the greater medical community. Otherwise patients, like those in our
study, will suffer from the effects of a poorly coordinated system.
How can we address the poor quality of metabolic monitoring and treatment on a
national level? To begin, research such as this study must continue so that we can better
understand how the current system of care operates and thus how it should change.
Subsequently, leaders in mental health must accordingly formulate recommendations and
guidelines to address the concerns raised by such research. The Mount Sinai guidelines
are a good example of how this can be done. An absolutely critical step, and perhaps also
the most challenging one, is to mobilize professional change. An effort is required by
academic leaders, continuing medical education groups, and professional organizations –
particularly the American Psychiatric Association – to drive awareness and
implementation of guidelines. The effort and collaboration of non-psychiatric
professional groups, such as the American Medical Association and American College of
Physicians, is also needed. These groups must assist in bringing mental health care closer
to the rest of medicine so that the problems of obesity and diabetes can be tackled in a
coordinated fashion (among other issues). It is particularly important to link-up primary
care clinicians and internal medicine specialists who focus on metabolic disorders with
networks of psychiatrists and other MHCs.
In addition to leveraging the intrinsic incentives of patient care and
professionalism, extrinsic financial incentives, tied to measurements, can be put in place
to drive the adoption of guidelines and recommendations. Thus lobbying at various
governmental levels, including Congress and the Center for Medicare and Medicaid
Services, should press forward to ensure appropriate reimbursement and parity for mental
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health services. As performance measurements and performance-based incentives
become more mainstream, and if they are effective at improving outcomes, one would
hope that these tools would also be used to drive the adoption of guidelines and
recommendations in the area of metabolic monitoring – and that appropriate
reimbursement would be tied to such activities. Nevertheless, performance measurements
alone, even in the absence of financial incentives, could drive change simply by drawing
attention to the importance of metabolic monitoring. Yet to implement performance
measurements on a large scale would require extensive improvements in information
technology and communication throughout the fragmented mental health system, a
scenario that appears unlikely in the near future in the absence of serious national
healthcare reform.
It will also be important for the concepts of quality control and of total quality
management to finally be absorbed and applied in a serious manner in American
healthcare. Medicine has remained far too insular and has a tremendous amount to learn
from other fields such as business operations management, manufacturing, and military
systems control. It will be necessary for leaders within medicine to acquaint themselves
with the concepts of quality management (94-98), and to retain experts from other fields
such as business and manufacturing in order to improve the quality of healthcare delivery
systems.
Setting aside broader issues of professional change and national healthcare
reforms, there does exist one very direct solution that could rapidly change clinician
behavior nationally, and it is based on what we have learned from clozapine regulation.
The manufacturers of clozapine require psychiatrists to submit the results of a blood cell
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count before the drug can be dispensed. A similar requirement to report biometrics (e.g.
BMI and waist-size), in order for a pharmacy to dispense an antipsychotic, would rapidly
alter psychiatric practice.

Future Research Directions

Beyond the content of this study, there is much work to be done. It would be
useful to better understand how rates of documentation relate to actual behaviors, for
example by comparing documentation of laboratory orders to laboratory transactions. It
would also be interesting to determine if there are systemic differences between the
documentation behavior of MHCs and PCCs, which one might suspect could be due to
differences in professional culture, such as the high priority that MHCs may place on
privacy relative to PCCs as a result of their training.
It is also critical to study whether the adoption of monitoring guidelines, such as
those from Mount Sinai, actually improve outcomes (e.g. minimizes weight gains or
decreases diabetes conversion rates). In order to drive individual and organizational
change in the era of evidence-based medicine, proof that certain behaviors are linked to
improved outcomes is critical. Then, if it is found to be true that metabolic monitoring by
MHCs does indeed improve outcomes in areas such as weight gain and diabetes, we need
in turn to better understand how to change clinician behavior such that guidelines will be
adopted rapidly. An understanding of how to drive systemic change in clinical behavior
might be found in the analysis of historical attempts to do so, or through cross-pollination
by examining the literature on how other service industries improve quality through total
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quality management systems such as six-sigma (94-98). In addition to incorporating
guidelines into practice and measuring their impact, such guidelines should be regularly
updated to incorporate new tools as they emerge (e.g. promising genetic and metabolic
tests, such as TNF-alpha, which were discussed in the Introduction).
Once a metabolic problem is recognized, the next step is intervention, and so
researchers must also continue to create new interventions – and to verify the value of
those that are used in current practice. Weight gain that results from antipsychotic
treatment may require interventions that differ from those that are used for other types of
weight gain. For example, one might ask: what are the relative benefits of changing
antipsychotic dose, changing antipsychotic drug, consulting a nutritionist, or starting
pharmacotherapy (e.g. metformin) for weight-gain? These and similar questions would be
valuable to answer. Indeed, some researchers have already started to do so, a subject that
we reviewed in the Introduction.

Conclusion

In this cross-sectional study of 123 overweight or obese US veterans with
psychotic disorders, 97% of whom were taking an antipsychotic, we determined with
statistical significance that mental health clinicians identify, monitor and intervene for
metabolic disorders, such as weight gain and hyperglycemia, at much lower rates than
primary care physicians, and such rates are too low. We suspect that this is a problem of
systemic, not individual, omission. Our findings are disconcerting given the growing
evidence that the antipsychotics prescribed by mental health clinicians – particularly
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second-generation antipsychotics – are linked to the development of metabolic
dysfunction. In order to address this system-wide pattern of clinician behavior, which
may be leading to serious adverse consequences for patients, we believe that
organizational and operational systems must be changed, and that quality control systems
must be instituted. Changes to the status quo ought to occur as soon as possible on both a
local and national level so as to prevent harm to patients. Otherwise patients may
continue to develop higher rates of preventable weight gain, diabetes, and metabolic
syndrome – along with the life-threatening co-morbidities that are associated with such
conditions.

59

APPENDIX

TABLES

Table 1: Subject Race/Ethnicity (N=123)
Percent
Not Documented

20%

White

56%

Hispanic

2%

African-American

21%

Other

1%

Table 2: Subject Gender (N=123)
Percent
Male
Female

93%
7%
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Table 3: Age, Weight, BMI, and Number of Routine Office Visits (N=123)
Number of Routine
Visits
AGE

WEIGHT

Primary

Mental

(years)

(pounds)

BMI

Care

Health

Mean

54

218

32.4

3.4

15.6

Median

54

215

31.3

2.0

12.0

Mode

54

233

31.7

2.0

12.0

Minimum

31

137

25.0

1.0

1.0

Maximum

85

312

50.5

41.0

59.0

Range

54

175

25.5

40.0

58.0

8

35

5.4

4.0

11.1

Standard
Deviation
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Table 4: Subject Co-morbidities (N=123)
Percent
Diabetes Type I

1%

Diabetes Type II

23%

Hypertension

57%

Hypercholesterolemia

30%

Dyslipidemia

40%

Osteoarthritis; Degenerative
Joint Disease

19%

Obstructive Sleep Apnea

10%

Hypothyroidism

5%

Metabolic Syndrome

0%

Coronary Artery Disease

9%

Any Smoking (current)

51%

Any Alcohol Use (current)

21%

High Alcohol Use (current)
(women >7 drinks per week;
men >14 drinks per week)

9%
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Table 5: Rates of Antipsychotic Therapy (N=123)
Percent
Prescribed First Generation Antipsychotic

37%

Prescribed Second Generation Antipsychotic

85%

Prescribed at Least One Antipsychotic of
Any Type

97%

Prescribed Both a First and Second
Generation Antipsychotic

25%

Aripiprazole (Abilify)

10%

Clozapine (Clozaril)

11%

Olanzapine (Zyprexa)

22%

Quetiapine (Seroquel)

24%

Risperidone (Risperdal)

29%

Ziprasidone (Geodon)

8%

Table 6: Documentation of Biometrics in Visit Notes (N=123)
95% CI

Waist size

Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

0%

0%

-

-

-

Weight

85%

11%

0.66

0.82

<0.001

Height

59%

2%

0.48

0.66

<0.001

BMI

48%

0%

0.39

0.57

<0.001
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Table 7: Identification of Weight Issues Documented in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

28%

13%

0.06

0.25

<0.005

26%

15%

0.01

0.21

<0.015

39%

17%

0.11

0.33

<0.001

45%

28%

0.04

0.28

<0.005

10%

12%

-0.10

0.05

0.730

28%

4%

0.15

0.32

<0.001

Identified weight as an issue in
problem list
Identified weight as an issue in
history
Identified weight as an issue in
assessment and plan
Identified weight as an issue in
at least one of the following:
problem list; history; assessment
and plan
Identified link between weight
and antipsychotics
Identified weight loss as a
therapy for a diagnosis other
than obesity
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Table 8: Tests Ordered in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

Blood glucose

50%

4%

0.36

0.55

<0.001

TSH

15%

4%

0.04

0.19

<0.005

Urinalysis

14%

0%

0.08

0.20

<0.001

Lipid panel

71%

2%

0.61

0.77

<0.001

Hemoglobin A1C

25%

2%

0.16

0.32

<0.001
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Table 9: Interventions For Weight Loss Documented in Visit Notes (N=123)
95% CI
Primary

Mental

Lower

Upper

Care

Health

Bound

Bound

P-value

Made dietary recommendations to
patient

57%

25%

0.20

0.43

<0.001

46%

22%

0.12

0.35

<0.001

42%

19%

0.12

0.35

<0.001

21%

3%

0.10

0.26

<0.001

1%

0%

-0.01

0.02

0.158

2%

4%

-0.06

0.03

0.764

2%

5%

-0.07

0.02

0.846

3%

6%

-0.08

0.03

0.823

Made exercise recommendations to
patient
Made exercise and dietary
recommendations to patient
Ordered at least one referral for weight
management
Considered or ordered
pharmacotherapy for weight loss
Considered or ordered change of
antipsychotic medication due to weight
Considered or ordered change of
antipsychotic dose due to weight
Considered or ordered change of
antipsychotic medication and/or dose
due to weight
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DATA ENTRY FORMS
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